
Hiroshi Shiku

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2568310/publications.pdf Version: 2024-02-01



Ηιροςμι ζηικιι

#	Article	IF	CITATIONS
1	Engineering hybrid exosomes by membrane fusion with liposomes. Scientific Reports, 2016, 6, 21933.	3.3	447
2	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
3	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. Immunity, 2000, 13, 265-276.	14.3	315
4	De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood, 2002, 99, 815-821.	1.4	273
5	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood, 2008, 111, 1357-1365.	1.4	202
6	Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. American Journal of Hematology, 2002, 69, 247-254.	4.1	178
7	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR. Cancer Research, 2009, 69, 9003-9011.	0.9	174
8	Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt DIC. American Journal of Hematology, 2003, 74, 17-22.	4.1	166
9	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	8.2	164
10	CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10902-10906.	7.1	152
11	Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thrombosis Research, 2007, 120, 187-193.	1.7	143
12	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
13	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2268-2277.	7.0	139
14	Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nature Communications, 2018, 9, 435.	12.8	139
15	Outcome of Disseminated Intravascular Coagulation in Relation to the Score when Treatment was Begun. Thrombosis and Haemostasis, 1995, 74, 848-852.	3.4	138
16	Reduced expression ofnm23-H1, but not ofnm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. International Journal of Cancer, 1993, 55, 66-71.	5.1	132
17	Safety and persistence of WT1-specific T-cell receptor geneâ^'transduced lymphocytes in patients with AML and MDS. Blood, 2017, 130, 1985-1994.	1.4	127
18	Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFâ€cleaving protease activity. Transfusion, 2002, 42, 572-580.	1.6	121

#	Article	IF	CITATIONS
19	Exosomeâ€mediated regulation of tumor immunology. Cancer Science, 2018, 109, 2998-3004.	3.9	119
20	mRNA expression of leukemiaâ€associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. International Journal of Cancer, 2004, 108, 704-711.	5.1	118
21	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. Journal of Experimental Medicine, 2005, 201, 681-686.	8.5	118
22	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research, 2010, 16, 2781-2791.	7.0	118
23	Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Science, 2008, 99, 601-607.	3.9	117
24	Nanogel-Based Immunologically Stealth Vaccine Targets Macrophages in the Medulla of Lymph Node and Induces Potent Antitumor Immunity. ACS Nano, 2014, 8, 9209-9218.	14.6	117
25	HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan. Clinical Cancer Research, 2006, 12, 7397-7405.	7.0	115
26	Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood, 2011, 118, 1495-1503.	1.4	114
27	De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica, 2008, 93, 1195-1202.	3.5	113
28	Tissue Factor Expression and Metastatic Potential of Colorectal Cancer. Thrombosis and Haemostasis, 1998, 80, 894-898.	3.4	112
29	Presentation of a major histocompatibility complex class 1–binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide–truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood, 2002, 99, 3717-3724.	1.4	112
30	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9253-9257.	7.1	102
31	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	8.2	102
32	Frequent Glycine-to-Aspartic Acid Mutations at Codon 12 of c-Ki-rasGene in Human Pancreatic Cancer in Japanese. Japanese Journal of Cancer Research, 1990, 81, 135-140.	1.7	95
33	CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class l–αβTCR interaction and become IL-10-producing active regulatory cells. International Immunology, 2008, 20, 937-947.	4.0	95
34	Agonist-Induced Regulation of Myosin Phosphatase Activity in Human Platelets Through Activation of Rho-Kinase. Blood, 1999, 93, 3408-3417.	1.4	94
35	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Journal of Translational Medicine, 2013, 11, 246.	4.4	94
36	Distinguishing Pancreatic Carcinoma From Other Periampullary Carcinomas by Analysis of Mutations in the Kirsten-ras Oncogene. Annals of Surgery, 1991, 214, 657-662.	4.2	93

#	Article	IF	CITATIONS
37	De Novo CD5+ Diffuse Large B-Cell Lymphomas Express VH Genes With Somatic Mutation. Blood, 1998, 91, 1145-1151.	1.4	92
38	IFN-Î ³ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. Journal of Immunology, 2005, 175, 4433-4440.	0.8	92
39	Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation. Thrombosis Research, 2001, 104, 1-6.	1.7	88
40	T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunity, 2007, 7, 9.	3.2	87
41	Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. British Journal of Haematology, 2000, 109, 288-295.	2.5	83
42	Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.9	80
43	Hematopoietic origin of hepatic stellate cells in the adult liver. Blood, 2008, 111, 2427-2435.	1.4	79
44	High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. American Journal of Hematology, 2003, 72, 1-7.	4.1	75
45	Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood, 2018, 132, 1134-1145.	1.4	73
46	Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Scientific Reports, 2015, 5, 14896.	3.3	70
47	Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene, 1998, 16, 1587-1591.	5.9	69
48	Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. , 1996, 51, 255-260.		68
49	De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. British Journal of Haematology, 1999, 105, 1133-1139.	2.5	68
50	Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. International Journal of Cancer, 2007, 120, 2178-2184.	5.1	68
51	Molecular cloning and functional expression of the second mousenm23/NDP kinase gene,nm23-M2. FEBS Letters, 1992, 309, 358-362.	2.8	64
52	Gene expression profiling of peripheral T-cell lymphoma including γδT-cell lymphoma. Blood, 2009, 113, 1071-1074.	1.4	64
53	Survival of human leukaemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein. British Journal of Haematology, 1999, 105, 701-710.	2.5	62
54	Expression ofnm23-Hl andnm23-H2 Proteins in Prostate Carcinoma. Japanese Journal of Cancer Research, 1993, 84, 1050-1054.	1.7	61

#	Article	IF	CITATIONS
55	Expression of ?2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconjugate Journal, 1995, 12, 894-900.	2.7	61
56	Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14571-14576.	7.1	61
57	Expression of DCC Protein in Colorectal Tumors and Its Relationship to Tumor Progression and Metastasis. Oncology, 1999, 56, 134-141.	1.9	60
58	The Blood Group P1 Synthase Gene Is Identical to the Gb3/CD77 Synthase Gene. Journal of Biological Chemistry, 2003, 278, 44429-44438.	3.4	60
59	Rapid αβ TCR-mediated responses in γδT cells transduced with cancer-specific TCR genes. Gene Therapy, 2009, 16, 620-628.	4.5	59
60	Activated t-lymphocytes with polyclonal gammopathy in patients with human t-lymphotropic virus type i?associated myelopathy. Annals of Neurology, 1988, 24, 280-282.	5.3	58
61	Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. , 1998, 58, 189-194.		58
62	Regulation of Myosin Phosphatase Through Phosphorylation of the Myosin-Binding Subunit in Platelet Activation. Blood, 1997, 90, 3936-3942.	1.4	57
63	Protein kinase C–catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. Blood, 2001, 97, 3798-3805.	1.4	57
64	A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes. Journal of Leukocyte Biology, 2005, 78, 921-929.	3.3	57
65	siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Therapy, 2012, 19, 959-966.	4.5	57
66	Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: Development of a CD5 signature. Cancer Science, 2006, 97, 868-874.	3.9	56
67	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.7	56
68	Cell-mediated cytotoxicity for cultured autologous melanoma cells. International Journal of Cancer, 1979, 24, 34-44.	5.1	55
69	Hemostatic molecular markers before the onset of disseminated intravascular coagulation. American Journal of Hematology, 1999, 60, 273-278.	4.1	55
70	CD8 ⁺ CD122 ⁺ CD49d ^{low} regulatory T cells maintain T-cell homeostasis by killing activated T cells via Fas/FasL-mediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2460-2465.	7.1	55
71	Substrate Specificity of β1,4-N-Acetylgalactosaminyltransferase in Vitro and in cDNA-transfected Cells. Journal of Biological Chemistry, 1995, 270, 6149-6155.	3.4	54
72	Features of early gastric cancer and gastric adenoma by enhanced-magnification endoscopy. Journal of Gastroenterology, 2006, 41, 332-338.	5.1	54

#	Article	lF	CITATIONS
73	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine, 2014, 32, 5901-5907.	3.8	54
74	Interleukin-17 Induces an Atypical M2-Like Macrophage Subpopulation That Regulates Intestinal Inflammation. PLoS ONE, 2014, 9, e108494.	2.5	53
75	Exosomal regulation of lymphocyte homing to the gut. Blood Advances, 2019, 3, 1-11.	5.2	52
76	Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGE. Clinical Cancer Research, 2005, 11, 5581-5589.	7.0	51
77	Localization and subcellular distribution of cellular ras gene products in rat brain. Molecular Brain Research, 1989, 5, 31-44.	2.3	50
78	Reprogramming of human postmitotic neutrophils into macrophages by growth factors. Blood, 2004, 103, 2973-2980.	1.4	50
79	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumorâ€specific CD8 ⁺ T cells. European Journal of Immunology, 2009, 39, 241-253.	2.9	50
80	Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 185-192.	1.7	48
81	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. Journal of Immunology, 2010, 185, 3768-3776.	0.8	47
82	Attenuation of Interleukin 2 Signal in the Spleen Cells of Complex Ganglioside-lacking Mice. Journal of Biological Chemistry, 1999, 274, 13744-13747.	3.4	46
83	A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. European Journal of Immunology, 2000, 30, 3338-3346.	2.9	46
84	Analysis of peripheral and local antiâ€ŧumor immune response in esophageal cancer patients after NYâ€ESOâ€1 protein vaccination. International Journal of Cancer, 2008, 123, 2362-2369.	5.1	46
85	Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunology, Immunotherapy, 2011, 60, 1289-1297.	4.2	46
86	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.9	46
87	Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Research, 2003, 63, 60-6.	0.9	46
88	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 2009, 27, 6854-6861.	3.8	45
89	In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope. Clinical Cancer Research, 2006, 12, 1921-1927.	7.0	44
90	Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. American Journal of Hematology, 1997, 55, 183-187.	4.1	43

#	Article	IF	CITATIONS
91	BaxInduction Activates Apoptotic Cascade via Mitochondrial CytochromecRelease andBaxOverexpression Enhances Apoptosis Induced by Chemotherapeutic Agents in DLD-1 Colon Cancer Cells. Japanese Journal of Cancer Research, 2000, 91, 1264-1268.	1.7	43
92	Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. American Journal of Cardiology, 2000, 85, 1054-1059.	1.6	43
93	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemotherapy and Pharmacology, 2000, 46, S77-S82.	2.3	43
94	Importance of CD4+ Helper T-cells in Antitumor Immunity. International Journal of Hematology, 2003, 77, 435-438.	1.6	43
95	Importance of CD80/CD86–CD28 interactions in the recognition of target cells by CD8+CD122+regulatory T cells. Immunology, 2008, 124, 121-128.	4.4	43
96	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34+ Macrophage Progenitors. International Journal of Hematology, 2002, 75, 269-276.	1.6	40
97	Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunology, Immunotherapy, 2008, 57, 1429-1437.	4.2	40
98	Differential Regulatory Function of Resting and Preactivated Allergen-Specific CD4+CD25+ Regulatory T Cells in Th2-Type Airway Inflammation. Journal of Immunology, 2008, 181, 6889-6897.	0.8	40
99	Development of a novel redirected T-cell–based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Blood, 2013, 121, 4894-4901.	1.4	40
100	Decreased Plasma Tissue Factor Pathway Inhibitor Levels in Patients with Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1995, 73, 010-014.	3.4	39
101	Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor. PLoS ONE, 2013, 8, e56820.	2.5	39
102	Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy. Cancer Immunology Research, 2014, 2, 249-262.	3.4	38
103	Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 229-233.	1.7	37
104	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. European Journal of Immunology, 2010, 40, 787-796.	2.9	37
105	A HER2/NEU-derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes. International Journal of Cancer, 2000, 87, 553-558.	5.1	36
106	Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncolmmunology, 2016, 5, e1211218.	4.6	36
107	IL-2-Dependent ATL cell lines with phenotypes differing from the original leukemia cells. Leukemia Research, 1991, 15, 619-625.	0.8	35
108	Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thrombosis and Haemostasis, 2005, 93, 153-159.	3.4	34

#	Article	IF	CITATIONS
109	Glucocorticoidâ€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€specific CD8 ⁺ T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	3.9	34
110	A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression. Molecular Therapy - Nucleic Acids, 2012, 1, e63.	5.1	34
111	IFN-Î ³ -dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis, 2009, 30, 1408-1415.	2.8	33
112	Established IL-2-dependent double-negative (CD4-CD8-) TCRαβ/CD3+ATL cells: induction of CD4 expression. British Journal of Haematology, 1994, 88, 234-241.	2.5	31
113	Hemostatic Molecular Markers Before Onset of Disseminated Intravascular Coagulation in Leukemic Patients. Seminars in Thrombosis and Hemostasis, 1998, 24, 293-297.	2.7	31
114	Increased Soluble Fibrin in Plasma of Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 233-240.	1.7	31
115	Expression ofc-myc Oncogens Product andras Family Oncogene Products in Various Human Malignant Lymphomas Defined by Immunohistochemical Techniques. Cancer, 1988, 62, 2085-2093.	4.1	30
116	Acute myeloid leukemia with t(8;21)(q22;q22) manifesting as granulocytic sarcomas in the rhinopharynx and external acoustic meatus at relapse after high-dose cytarabine: case report and review of the literature. The Hematology Journal, 2004, 5, 84-89.	1.4	30
117	Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. American Journal of Hematology, 1995, 49, 1-5.	4.1	29
118	Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. , 1996, 52, 165-170.		29
119	Contrast-enhanced ultrasound examination of lymph nodes in different types of lymphoma. Cancer Detection and Prevention, 2006, 30, 188-191.	2.1	29
120	Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY‑ESO‑1 and MAGE‑A4 in high‑grade soft‑tissue sarcoma. Oncology Letters, 2019, 17, 3937-3943.	1.8	29
121	Distinguishing functional exosomes and other extracellular vesicles as a nucleic acid cargo by the anionâ€exchange method. Journal of Extracellular Vesicles, 2022, 11, e12205.	12.2	29
122	Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. American Journal of Hematology, 2000, 65, 35-40.	4.1	28
123	Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leukemia Research, 2006, 30, 1235-1239.	0.8	28
124	Induction of regulatory T cell–resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	1.4	28
125	Intratumoral Injection of Propionibacterium acnes Suppresses Malignant Melanoma by Enhancing Th1 Immune Responses. PLoS ONE, 2011, 6, e29020.	2.5	28
126	First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Reports in Oncology, 2019, 12, 147-156.	0.7	28

#	Article	IF	CITATIONS
127	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. Cancer Immunology, Immunotherapy, 2019, 68, 1195-1209.	4.2	27
128	Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. , 1999, 61, 238-242.		26
129	Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 5-9.	1.7	26
130	Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detection and Prevention, 2005, 29, 256-259.	2.1	26
131	Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thrombosis Research, 2005, 116, 307-312.	1.7	26
132	Pleiotropic role of histone deacetylases in the regulation of human adult erythropoiesis. British Journal of Haematology, 2006, 135, 242-253.	2.5	26
133	Tâ€cell receptor gene therapy targeting melanomaâ€associated antigenâ€A4 inhibits human tumor growth in nonâ€obese diabetic/SCID/l³c ^{null} mice. Cancer Science, 2012, 103, 17-25.	3.9	26
134	Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncology Letters, 2016, 12, 4493-4504.	1.8	26
135	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10, e003811.		26
136	Immunohistochemical Analysis of Expression of nm23-H1/Nucleoside Diphosphate Kinase in Human Thyroid Carcinomas: Lack of Correlation Between Its Expression and Lymph Node Metastasis. Thyroid, 1993, 3, 105-109.	4.5	25
137	Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16;21)(p11;q22): frequent expression of CD56 and interleukin-2 receptor α chain. British Journal of Haematology, 1999, 105, 711-719.	2.5	25
138	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. American Journal of Hematology, 2004, 75, 179-189.	4.1	25
139	Post-immune UV irradiation induces Tr1-like regulatory T cells that suppress humoral immune responses. International Immunology, 2008, 20, 57-70.	4.0	25
140	Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. International Journal of Hematology, 2015, 102, 188-194.	1.6	25
141	MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC Cancer, 2020, 20, 606.	2.6	25
142	Differential Association of Protein Ser/Thr Phosphatase Types 1 and 2A with the Cytoskeleton upon Platelet Activation. Thrombosis and Haemostasis, 1996, 76, 1053-1062.	3.4	25
143	Adult T cell leukaemia cells are of CD4+CDw29+T cell origin and secrete a B cell differentiation factor. British Journal of Haematology, 1989, 72, 370-377.	2.5	24
144	Cyclin D1 expression is useful as a prognostic indicator for advanced esophageal carcinomas, but not for superficial tumors. Digestive Diseases and Sciences, 2000, 45, 864-869.	2.3	24

#	Article	IF	CITATIONS
145	Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. Gastrointestinal Endoscopy, 2001, 54, 92-96.	1.0	24
146	Comparison of the Responses of Global Tests of Coagulation with Molecular Markers of Neutrophil, Endothelial, and Hemostatic System Perturbation in the Baboon Model of E. coli Sepsis. Thrombosis and Haemostasis, 2001, 86, 1489-1494.	3.4	24
147	HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations. Gene Therapy, 2002, 9, 879-888.	4.5	24
148	Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood, 2012, 119, 368-376.	1.4	24
149	Diagnosis of Disseminated Intravascular Coagulation by Hemostatic Molecular Markers. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 017-022.	2.7	24
150	CD19-Negative Diffuse Large B-Cell Lymphoma Shows High Serum LDH Level and Poor Prognosis Blood, 2005, 106, 1924-1924.	1.4	24
151	Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells. Cancer Genetics and Cytogenetics, 2006, 164, 118-121.	1.0	23
152	Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-beta1. British Journal of Haematology, 1999, 105, 470-477.	2.5	22
153	Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. British Journal of Haematology, 2001, 114, 681-689.	2.5	22
154	Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. Thrombosis and Haemostasis, 2003, 89, 660-665.	3.4	22
155	Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thrombosis and Haemostasis, 2004, 92, 132-139.	3.4	22
156	Elevated Plasma Levels of Fibrin Degradation Productsby Granulocyte-Derived Elastase in Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 391-400.	1.7	22
157	Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv(16) chromosome: Case report and review of literature. Leukemia Research, 2006, 30, 1053-1057.	0.8	22
158	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	4.2	22
159	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. Journal of Controlled Release, 2022, 347, 175-182.	9.9	22
160	Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. Cancer Genetics and Cytogenetics, 1988, 34, 77-88.	1.0	21
161	T cell receptor-mediated stimulation of mouse thymocytes induces up-regulation of the GM2/GD2 synthase gene. FEBS Letters, 1995, 358, 79-83.	2.8	20
162	The Membrane Proteinase 3 Expression on Neutrophils Was Downregulated After Treatment With Infliximab in Patients With Rheumatoid Arthritis. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 186-192.	1.7	20

#	Article	IF	CITATIONS
163	Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia. Clinical Cancer Research, 2016, 22, 4405-4416.	7.0	20
164	Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunology, Immunotherapy, 2021, 70, 3081-3091.	4.2	20
165	Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. , 1999, 60, 94-98.		19
166	Hemostatic Abnormalities in Patients With Thrombotic Complications on Maintenance Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 100-103.	1.7	19
167	Additional t(11;17)(q23;q21) in a patient with Philadelphia-positive mixed lineage antigen-expressing leukemia. Cancer Genetics and Cytogenetics, 2001, 126, 8-12.	1.0	19
168	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine, 2006, 45, 733-737.	0.7	19
169	Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thrombosis Research, 2007, 119, 447-452.	1.7	19
170	Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) αβ genes transduced to CD8+ T cells. Gene Therapy, 2008, 15, 695-699.	4.5	19
171	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. International Journal of Cancer, 2011, 129, 1126-1136.	5.1	19
172	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Science, 2020, 111, 1958-1968.	3.9	19
173	Hemostatic Abnormalities and Changes Following Bone Marrow Transplantation. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 341-350.	1.7	18
174	PROTEINASE 3 EXPRESSION ON NEUTROPHIL MEMBRANES FROM PATIENTS WITH INFECTIOUS DISEASE. Shock, 2006, 26, 128-133.	2.1	18
175	Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. American Heart Journal, 2001, 142, 5A-12A.	2.7	17
176	Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): A single-institution study of 224 Japanese AML patients. Leukemia Research, 2007, 31, 471-476.	0.8	17
177	Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation. , 1999, 61, 21-25.		16
178	Relationship between Development of Nephrotoxicity and Blood Concentration of Cyclosporine A in Bone-Marrow Transplanted Recipients Who Received the Continuous Intravenous Infusion. Biological and Pharmaceutical Bulletin, 2003, 26, 1115-1119.	1.4	16
179	Usefulness of Measurement of Reticulated Platelets for Diagnosis of Idiopathic Thrombocytopenic Purpura. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 253-261.	1.7	16
180	Elevated plasma levels of fibrin degradation products by granulocyte-derived elastase in patients with deep vein thrombosis. Thrombosis Research, 2005, 115, 53-57.	1.7	16

#	Article	IF	CITATIONS
181	Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. Journal of Immunological Methods, 2006, 314, 54-66.	1.4	16
182	UV irradiation after immunization induces type 1 regulatory T cells that suppress Th2-type immune responses via secretion of IL-10. Immunobiology, 2010, 215, 124-132.	1.9	16
183	2015 Guidance on cancer immunotherapy development in earlyâ€phase clinical studies. Cancer Science, 2015, 106, 1761-1771.	3.9	16
184	Plasma concentration of itraconazole and its antifungal prophylactic efficacy in patients with neutropenia after chemotherapy for acute leukemia. Journal of Infection and Chemotherapy, 1999, 5, 213-216.	1.7	15
185	Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. American Journal of Hematology, 2000, 64, 145-150.	4.1	15
186	Gastric mucosa-associated lymphoid tissue lymphoma with a focal high-grade component diagnosed by EUS and endoscopic mucosal resection for histologic evaluation. Gastrointestinal Endoscopy, 2000, 51, 752-755.	1.0	15
187	Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin. American Journal of Hematology, 2004, 77, 167-170.	4.1	15
188	Usefulness of Fully Automated Measurement of Reticulated Platelets Using Whole Blood. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 263-270.	1.7	15
189	Tumor-specific Crosslinking of GITR as Costimulation for Immunotherapy. Journal of Immunotherapy, 2010, 33, 925-934.	2.4	15
190	Guanine-Rich Sequences Are a Dominant Feature of Exosomal microRNAs across the Mammalian Species and Cell Types. PLoS ONE, 2016, 11, e0154134.	2.5	15
191	Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS ONE, 2016, 11, e0156643.	2.5	14
192	Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1377-1385.	2.0	14
193	Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 428-435.	0.8	13
194	CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. British Journal of Haematology, 2004, 125, 180-186.	2.5	13
195	Rho-kinase induces association of adducin with the cytoskeleton in platelet activation. Biochemical and Biophysical Research Communications, 2005, 332, 347-351.	2.1	13
196	Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor ?-positive and -negative human hematopoietic progenitors. Cancer Science, 2007, 98, 1597-1603.	3.9	13
197	Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus. Blood Coagulation and Fibrinolysis, 1997, 8, 303-307.	1.0	12
198	Gene expression profiling of diffuse large Bâ€cell lymphoma supervised by CD21 expression. British Journal of Haematology, 2008, 142, 562-570.	2.5	12

#	Article	IF	CITATIONS
199	Human bone marrow stromal cells simultaneously support <scp>B</scp> and <scp>T</scp> / <scp>NK</scp> lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. British Journal of Haematology, 2012, 157, 674-686.	2.5	12
200	Adoptive transfer of genetically modified Wilms' tumor 1–specific T cells in a novel malignant skull base meningioma model. Neuro-Oncology, 2013, 15, 747-758.	1.2	12
201	Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor. PLoS ONE, 2014, 9, e104669.	2.5	12
202	Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer. Leukemia, 2015, 29, 2393-2401.	7.2	12
203	NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma. Oncotarget, 2018, 9, 35997-36011.	1.8	12
204	A new differentiation antigen defining a subpopulation of mouse T cells. Nature, 1976, 261, 137-139.	27.8	11
205	Up-regulation of protein serine/threonine phosphatase type 2C during 1α,25-dihydroxyvitamin D3-induced monocytic differentiation of leukemic HL-60 cells. FEBS Letters, 1995, 375, 299-303.	2.8	11
206	Successful treatment with lowâ€dose splenic irradiation for massive splenomegaly in an elderly patient with hairyâ€cell leukemia. European Journal of Haematology, 2001, 67, 255-257.	2.2	11
207	Upregulated production of IL-6, but not IL-10, by interferon- \hat{l} ± induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells. The Hematology Journal, 2004, 5, 505-512.	1.4	11
208	Differential cell division history between neutrophils and macrophages in their development from granulocyte?macrophage progenitors. British Journal of Haematology, 2006, 135, 725-731.	2.5	11
209	Development of Mixed-Type Autoimmune Hemolytic Anemia and Evans' Syndrome following Chicken Pox Infection in a Case of Low-Titer Cold Agglutinin Disease. International Journal of Hematology, 2006, 84, 220-223.	1.6	11
210	Analysis of Clonal Relationship Using Single-Cell Polymerase Chain Reaction in a Patient with Concomitant Mantle Cell Lymphoma and Multiple Myeloma. International Journal of Hematology, 2001, 73, 383-385.	1.6	10
211	Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thrombosis Research, 2006, 117, 671-679.	1.7	10
212	Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: Association with low p14ARF expression. Leukemia Research, 2006, 30, 379-383.	0.8	10
213	Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia. European Journal of Haematology, 2006, 76, 18-22.	2.2	10
214	Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy, 2016, 8, 527-540.	2.0	10
215	A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 2013, 13, 3.	3.2	10
216	K-ras gene mutations in intrahepatic bile duct tumors of Syrian golden hamsters. , 1997, 66, 97-103.		9

K-ras gene mutations in intrahepatic bile duct tumors of Syrian golden hamsters. , 1997, 66, 97-103. 216

#	Article	IF	CITATIONS
217	State-of-the-Art Review : Elevated Tissue Factor Levels in Leukemic Cell Homogenate. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 14-17.	1.7	9
218	Hemostatic Abnormalities Following Bone Marrow Transplantation. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 125-132.	1.7	9
219	Plasma Levels of Heparin Cofactor II (HCII) and Thrombin-HCII Complex in Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 265-271.	1.7	9
220	Two Independent Clones in Myelodysplastic Syndrome Following Treatment of Acute Myeloid Leukemia. International Journal of Hematology, 2002, 75, 182-186.	1.6	9
221	Acute interstitial pneumonitis during chemotherapy for haematological malignancy. European Journal of Cancer Care, 2005, 14, 336-341.	1.5	9
222	Inhibition by Rho-kinase and protein kinase C of myosin phosphatase is involved in thrombin-induced shape change of megakaryocytic leukemia cell line UT-7/TPO. Cellular Signalling, 2005, 17, 321-330.	3.6	9
223	Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. American Journal of Hematology, 2005, 78, 1-6.	4.1	9
224	Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma. International Journal of Hematology, 2007, 85, 41-48.	1.6	9
225	Limited expression of cancer-testis antigens in renal cell carcinoma patients. Molecular and Clinical Oncology, 2013, 1, 326-330.	1.0	9
226	Stimulation through very late antigenâ€4 and â€5 improves the multifunctionality and memory formation of CD8 ⁺ TAcells. European Journal of Immunology, 2014, 44, 1747-1758.	2.9	9
227	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination Blood, 2007, 110, 1806-1806.	1.4	9
228	Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation. Oncotarget, 2017, 8, 30766-30780.	1.8	9
229	Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. American Journal of Hematology, 2000, 65, 210-214.	4.1	8
230	Acute promyelocytic leukemia with del(6)(p23). Leukemia Research, 2000, 24, 79-81.	0.8	8
231	Good or Poor Responses of Hemostatic Molecular Markers in Patients with Hematopoietic Disorders After Treatment of Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 71-77.	1.7	8
232	Bilateral Osteonecrosis of the Head of the Femur during Treatment with Retinoic Acid in a Young Patient with Acute Promyelocytic Leukemia. International Journal of Hematology, 2006, 83, 252-253.	1.6	8
233	Overcoming regulatory Tâ€cell suppression by a lyophilized preparation of <i>Streptococcus pyogenes</i> . European Journal of Immunology, 2013, 43, 989-1000.	2.9	8
234	Binding ofrasp21 to bands 4.2 and 6 of human erythrocyte membranes. FEBS Letters, 1988, 226, 291-296.	2.8	7

#	Article	IF	CITATIONS
235	State-of-the-Art Review : Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 110-112.	1.7	7
236	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. American Journal of Gastroenterology, 2000, 95, 2403-2404.	0.4	7
237	State-of-the-Art Review : Coagulation Tests and Anti-Phospholipid Antibodies in Patients Positive for Lupus Anticoagulant. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 144-150.	1.7	7
238	Endosonographic Images of Low-grade Lymphoma of Mucosa-associated Lymphoid Tissue After Radiotherapy. Journal of Clinical Gastroenterology, 2001, 33, 237-240.	2.2	7
239	Fluorescent In Situ Hybridization Analysis of Philadelphia Chromosome-Negative Chronic Myeloid Leukemia with the bcr/abl Fusion Gene. International Journal of Hematology, 2004, 80, 155-158.	1.6	7
240	Thrombomodulin accelerates activated protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. Blood Coagulation and Fibrinolysis, 2005, 16, 17-24.	1.0	7
241	Antigen-Receptor Gene-Modified T Cells For Treatment Of Glioma. Advances in Experimental Medicine and Biology, 2012, 746, 202-215.	1.6	7
242	Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status. International Journal of Oncology, 2018, 53, 713-724.	3.3	7
243	Changes of Hemostatic Molecular Markers After Gynecological Surgery. Clinical and Applied Thrombosis/Hemostasis, 2000, 6, 197-201.	1.7	6
244	Bcl-2 in Cell-Cycle Regulation of Hematopoietic Cells by Transforming Growth Factor-β1. Leukemia and Lymphoma, 2000, 39, 601-605.	1.3	6
245	IL-4 and IL-10 synergistically inhibit survival of human blood monocytes supported by GM-CSF. International Journal of Oncology, 2005, 26, 731.	3.3	6
246	Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells. Vaccine, 2013, 31, 2110-2118.	3.8	6
247	Tumor responses and early onset cytokine release syndrome in synovial sarcoma patients treated with a novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer Journal of Clinical Oncology, 2019, 37, 2530-2530.	1.6	6
248	Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers. Oncotarget, 2018, 9, 14909-14921.	1.8	6
249	Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe Journal of Medical Sciences, 2008, 54, E23-34.	0.2	6
250	EXPERIMENTAL MODELS AND THE ROLE OF RNA IN IMMUNOTHERAPY OF LEUKEMIA. Annals of the New York Academy of Sciences, 1973, 207, 430-441.	3.8	5
251	Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 × anti-c-ErbB-2 bispecific antibody. Cancer Immunology, Immunotherapy, 1999, 48, 456-462.	4.2	5
252	A Case of Acute Myeloid Leukemia with t(7;11)(p15;p15) Mimicking Myeloid Crisis of Chronic Myelogenous Leukemia. International Journal of Hematology, 2002, 76, 80-83.	1.6	5

 NY3EESO3EI protein glycosylated by yeast induces enhanced immune responses. Yeast, 2010, 27, 919- Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs a sensors. Oncolmmunology, 2017, 6, e1306617. Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule. Blood, 2015, 126, 4292-4292. Immunohistochemical and Semiquantitative Immunoblot Analyses of Nm23-H1 and H2 Isoforms in Normal Human Tissues Acta Histochemica Et Cytochemica, 1998, 31, 411-418. Semiquantitative immunoblot analysis of nm23-H1 and H2 Isoforms in adenocarcinomas of the lung: Prognostic significance. Pathology International, 2000, 50, 200-205. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia. 		5
 ²⁵⁴ sensors. Oncolmmunology, 2017, 6, e1306617. ²⁵⁵ Immunotherapy with Chimeric Antigen Receptor Targeting Intracellular WT1 Gene Product Complexed with HLA-a*24:02 Molecule. Blood, 2015, 126, 4292-4292. ²⁵⁶ Immunohistochemical and Semiquantitative Immunoblot Analyses of Nm23-H1 and H2 Isoforms in Normal Human Tissues Acta Histochemica Et Cytochemica, 1998, 31, 411-418. ²⁵⁷ Semiquantitative immunoblot analysis of nm23-H1 and H2 isoforms in adenocarcinomas of the lung: Prognostic significance. Pathology International, 2000, 50, 200-205. ²⁵⁸ Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497. ²⁵⁹ Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. ²⁶⁰ Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. 	s 4.6	
 with HLA-a*24:02 Molecule. Blood, 2015, 126, 4292-4292. Immunohistochemical and Semiquantitative Immunoblot Analyses of Nm23-H1 and H2 Isoforms in Normal Human Tissues Acta Histochemica Et Cytochemica, 1998, 31, 411-418. Semiquantitative immunoblot analysis of nm23-H1 and -H2 isoforms in adenocarcinomas of the lung: Prognostic significance. Pathology International, 2000, 50, 200-205. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. 		5
 Normal Human Tissues Acta Histochemica Et Cytochemica, 1998, 31, 411-418. Semiquantitative immunoblot analysis of nm23-H1 and -H2 isoforms in adenocarcinomas of the lung: Prognostic significance. Pathology International, 2000, 50, 200-205. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. 	1.4	5
 Prognostic significance. Pathology International, 2000, 50, 200-205. Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas. International Journal of Oncology, 2004, 24, 497. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. 	1.6	4
 transduction genes distinguish different subtypes of lýmphomas. International Journal of Oncology, 2004, 24, 497. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. 	1.3	4
 259 serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. International Journal of Oncology, 2005, 27, 1241. 260 Prognostic Impact of Aortic Calcification Index and Ankle-Arm Blood Pressure Indexin Patients under Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169. Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia. 	3.3	4
Hemodialysis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 161-169.	3.3	4
Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia.	1.7	4
Leukemia Research, 2006, 30, 106-108.	0.8	4
Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury. Journal of Hematology and Oncology, 2014, 7, 3.	17.0	4
263 HTLV-1 unrelated adult T-cell leukemia/lymphoma with unique phenotype and karyotype. , 2000, 64, 64-	56.	3
Adult acute myeloid leukemia cells do not express nonfunctional Ikaros isoforms. Blood, 2002, 100, 3436-3436.	1.4	3
²⁶⁵ Effect of direct infusion of antifungal agent on invasive pulmonary aspergillosis in a patient with acute leukemia. Journal of Infection and Chemotherapy, 2002, 8, 106-108.	1.7	3
Quantization and similarity measure selection for discrimination of lymphoma subtypes under k-nearest neighbor classification. , 2004, 5328, 6.		3
267 IL-3 can not replace GM-CSF in inducing human monocytes to differentiate into Langerhans cells. International Journal of Oncology, 0, , .	3.3	3
Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes. Cancer Immunology, Immunotherapy, 2015, 64, 903-909.	4.2	3
Relationship between T cell receptor clonotype and PDâ€1 expression of tumorâ€infiltrating lymphocyte in colorectal cancer. European Journal of Immunology, 2020, 50, 1580-1590.	s 2.9	3
270 Increased Hemostatic Molecular Markers in Patients Undergoing Anticoagulant Therapy. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 113-118.		

#	Article	IF	CITATIONS
271	Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood, 2015, 126, 97-97.	1.4	3
272	Gene Expression Profiling of Diffuse Large B-Cell Lymphomas Supervised by CD21 Expression Blood, 2006, 108, 2029-2029.	1.4	3
273	Myelodysplastic Syndrome of del 20q with Plasma Cell Dysplasia. Journal of Clinical and Experimental Hematopathology: JCEH, 2011, 51, 141-145.	0.8	2
274	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells, 2021, 10, 152.	4.1	2
275	Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor. Blood, 2016, 128, 1653-1653.	1.4	2
276	Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination. Anticancer Research, 2018, 38, 1435-1444.	1.1	2
277	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines, 2022, 10, 373.	3.2	2
278	Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy. Cancer Immunology, Immunotherapy, 2022, 71, 2743-2755.	4.2	2
279	LIPOPROTEIN(A) AND EFFECTIVE RENAL PLASMA FLOW RATE IN OLDER PATIENTS WITH ARTERIOSCLEROTIC DISEASES. Journal of the American Geriatrics Society, 1995, 43, 1067-1068.	2.6	1
280	High establishment efficiency of lymph node stromal cells which spontaneously produce multiple cytokines derived from adult T-cell leukemia/lymphoma patients. International Journal of Oncology, 1996, 9, 619-24.	3.3	1
281	Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: Potential utility for adoptive immunotherapy. Experimental Hematology, 2013, 41, 367-376.e1.	0.4	1
282	193. Efficacy and Safety of Immunotherapy with Chimeric Antigen Receptor Targeting WT1 and HLA-A24:02 pMHC Complex. Molecular Therapy, 2016, 24, S75-S76.	8.2	1
283	PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.4	1
284	Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination. Oncology Letters, 2018, 15, 3703-3711.	1.8	1
285	First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors Journal of Clinical Oncology, 2018, 36, e15176-e15176.	1.6	1
286	Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma Journal of Clinical Oncology, 2019, 37, TPS11074-TPS11074.	1.6	1
287	Distinct Characteristics of t(8;21) Acute Myeloid Leukemia with Active KIT Mutation Blood, 2005, 106, 3297-3297.	1.4	1
288	Tumor- and Immune Cell-Derived Exosomes. Drug Delivery System, 2014, 29, 152-159.	0.0	1

#	Article	IF	CITATIONS
289	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. American Journal of Gastroenterology, 2000, 95, 2403-2404.	0.4	1
290	Serological and Biochemical Characterization of Surface Antigens Expressed on Human Myeloid Cells and Identification of Six Distinct Antigen Systems. Acta Haematologica, 1988, 79, 61-67.	1.4	0
291	Rapid lethality of hosts by interleukin-12 following H-2 compatible allogeneic bone marrow transplantation: Reminiscence of gut-associated acute graft-versus-host reaction. International Journal of Oncology, 2002, 21, 795.	3.3	0
292	Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts. International Journal of Oncology, 2003, 22, 1135.	3.3	0
293	Early Tumor Regression Following Severe Lung Injury after Allogeneic Stem Cell Transplantation in a Patient with Renal Cell Carcinoma. Internal Medicine, 2007, 46, 291-293.	0.7	0
294	Feasibility of gene-immunotherapy using WT1-specific T-cell receptor gene transfer for infant acute lymphoblastic leukemia with MLL gene rearrangement. Blood Cancer Journal, 2011, 1, e10-e10.	6.2	0
295	Cancer immunotherapy; integration of T cell biology with nanogel- and vector-technology in translational research. Arthritis Research and Therapy, 2012, 14, .	3.5	0
296	Attempt to Harvest a Sufficient Number of Mononuclear Cells in an Appropriate Blood Product Volume By Modification of the Default Apheresis Setting. Therapeutic Apheresis and Dialysis, 2017, 21, 507-511.	0.9	0
297	[OPINION] Problems of cancer vaccine therapy development. Drug Delivery System, 2017, 32, 172-173.	0.0	0
298	Development of INSOLâ€ŧag for proteomeâ€wide protein handling and its application in protein array analysis. Genes To Cells, 2020, 25, 41-53.	1.2	0
299	Increased Membrane Proteinase 3 Expression on Neutrophils in Patients with Infectious Disease Blood, 2004, 104, 3806-3806.	1.4	0
300	Development of Novel Stem Cell Transplantation and Gene-Immunotherapy Using WT1-Specific T-Cell Receptor Gene Blood, 2009, 114, 3028-3028.	1.4	0
301	Polyvalent Cancer Vaccine with a Novel Antigen Delivery System, CHP (cholesterol bearing) Tj ETQq1 1 0.784314	rgBT /Ove	erlgck 10 T
302	Abstract 5615: Effects of corticosteroids on tumor immunity induced by anti-CTLA-4 mAb therapy in a mouse model. , 2010, , .		0
303	Abstract 4751: Peptide vaccine induces apoptosis of antigen-specific CD8+T cells. , 2010, , .		0
304	Augmented Expression of WT1-Specific TCR and Inhibition of Mispaired-TCR Formation In TCR-Gene Modified T-Cells Can Concomitantly Be Achieved Using a Novel Retroviral Vector with Silencers for Endogenous TCRs. Blood, 2010, 116, 1020-1020.	1.4	0
305	Engineering of Human T-Cells with a Novel Aurora-A Kinase-Specific T-Cell Receptor Gene Transfer Confers Anti-Leukemia Reactivity. Blood, 2010, 116, 4290-4290.	1.4	0
306	A clinical trial of combined immunotherapy with MAGE-A4 peptide and cultured T lymphocyte for patients with head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2011, 37, 366-369.	0.1	0

#	Article	IF	CITATIONS
307	Forced Expression of CC Chemokine Receptor 2 Enhances Anti-Cancer Reactivity Mediated by T Lymphocytes Beforehand Redirected Toward WT1 Inside the Tumor Microenvironment. Blood, 2011, 118, 2059-2059.	1.4	0
308	The possibility of antigenic peptide, protein and DNA delivery by percutaneous vaccination. Drug Delivery System, 2012, 27, 194-201.	0.0	0
309	Therapeutically Infused Redirected T Cells Targeting WT1 Successfully Inhibited Leukemia Stem Cells in Vivo. Blood, 2012, 120, 4221-4221.	1.4	0
310	Abstract B11: Control of in vivo spatiotemporal dynamics of antigen and adjuvant by a delivery system CHP nanogel markedly improves the immunogenicity and antitumor efficacy of long peptide cancer vaccine , 2013, , .		0
311	Abstract CT212: Adoptive transfer of wild-type TCR gene transduced T lymphocytes targeting MAGE-A4 antigen to patients with refractory esophageal cancer. , 2014, , .		0
312	Tumor-Specific TCR-Engineered Donor Lymphocyte Infusion Therapy with Reduced GvHD Induction Utilizing Novel Retrovirus Vector Silencing Endogenous TCR Expression. Blood, 2014, 124, 656-656.	1.4	0
313	Abstract B34: Signal transducing adaptor protein 2 (STAP2) has the crucial role in maintaining the CTL function of memory T cells. , 2015, , .		0
314	Targeting Aurora Kinase with a Superior T-Cell Receptor Gene-Transfer Vector. Blood, 2015, 126, 4291-4291.	1.4	0
315	A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy. PLoS ONE, 2016, 11, e0156896.	2.5	0
316	Tumor-Specific Donor Lymphocyte Infusion for Tumor Relapse after MHC-Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2157-2157.	1.4	0
317	Abstract PR02: Antigen delivery targeting tumor-infiltrating macrophages leads to eradication of tumor highly resistant to immune checkpoint inhibitors. , 2017, , .		0
318	Nanogel antigen DDS toward overcoming immune resistance of cancer. Drug Delivery System, 2020, 35, 64-69.	0.0	0
319	Biliary Carcinomas Induced in the Hamster. , 2009, , 69-94.		0